Welcome to our dedicated page for Novavax SEC filings (Ticker: NVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Novavax, Inc. (NASDAQ: NVAX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Novavax is a vaccine-focused biotechnology company that reports on its financial condition, material agreements, capital structure and key product and partnership developments through forms such as 10-K, 10-Q and 8-K.
Current Reports on Form 8-K for Novavax frequently address material events tied to its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, the Matrix-M® adjuvant platform and major collaborations. Examples include disclosures about the collaboration and license agreement with Sanofi, marketing authorization transfers for Nuvaxovid in the European Union and United States that trigger milestone payments, amendments expanding Sanofi’s license to use Matrix-M in pandemic influenza vaccine candidates, and milestone payments and royalties associated with partners such as Takeda. Other 8-K filings describe site consolidation transactions in Maryland, non-cash impairment charges, and convertible senior note exchanges and issuances that shape the company’s capital structure.
Periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide detail on Novavax’s revenue components, including product sales, supply sales and licensing, royalties and other revenue, as well as research and development and selling, general and administrative expenses. They also expand on risk factors related to regulatory approvals, manufacturing, partnerships and market adoption of its vaccines.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in clear language. Users can quickly see key points from lengthy 10-K and 10-Q reports, understand the impact of 8-K announcements on partnerships and financing, and review information about potential equity issuance and debt obligations, including convertible senior notes. The filings page also surfaces insider and executive-related filings, such as Forms 3, 4 and 5, when available, to help track equity ownership changes.
All documents are updated in near real time as they are posted to the SEC’s EDGAR system, allowing investors and researchers to review Novavax’s official disclosures, assess how collaboration agreements and regulatory decisions affect the business, and follow the evolution of its vaccine and adjuvant platform through formal reporting.
Bank of America Corporation filed an amendment to a Schedule 13G disclosing beneficial ownership of 6,655,398 shares of Novavax Inc. The filing states this stake represents 4.1% of the class, calculated using 162,935,945 outstanding shares as of February 16, 2026. The statement attributes shared voting power of 6,653,929 and shared dispositive power of 6,655,398 across Bank of America and specified subsidiaries.
Novavax, Inc. is asking stockholders to vote at its June 18, 2026 virtual annual meeting on director elections, executive pay and key equity plan changes. The proxy highlights 2025 results, including $1.1 billion total revenue, a 42% reduction in non‑GAAP combined R&D and SG&A expenses compared to 2024, and a year‑end cash position of $857 million.
Stockholders are being asked to elect three Class I directors, approve a non‑binding say‑on‑pay vote, and ratify Ernst & Young LLP as auditor. Novavax also seeks to add 9.4 million shares to its 2015 Stock Incentive Plan and 1 million shares to its Employee Stock Purchase Plan, while emphasizing independent board leadership, committee oversight and a performance‑linked, at‑risk executive compensation program.
Novavax, Inc. EVP of R&D Robert Edward Walker received new equity compensation awards. He was granted stock options covering 99,500 shares of common stock at an exercise price of $8.46 per share, expiring on April 14, 2036.
The option vests 25% on the first anniversary of the April 14, 2026 grant date, with the remaining 75% vesting in equal monthly installments over the following three years, subject to continued employment. He also received 66,000 restricted stock units, each representing one share of common stock, vesting in three equal annual installments over three years, also contingent on continued employment.
NOVAVAX INC executive Robert Edward Walker, EVP, R&D, filed an initial ownership report showing equity awards and common stock holdings. The filing lists stock options to purchase 11,500 shares of common stock at $6.97 expiring on March 7, 2033, 22,510 shares at $10.11 expiring on March 3, 2035, and 18,826 shares at $8.39 expiring on March 2, 2036.
He also holds restricted stock units covering 47,600, 29,490 and 26,300 shares of common stock, plus 34,386 shares of common stock directly. Footnotes describe standard vesting schedules over three to four years, tied to continued employment.
Shah Capital files Amendment No. 6 to its Schedule 13D on Novavax, Inc., updating its ownership and activist intentions. The filing shows Shah Capital Management and related entities beneficially owning up to 14,845,097 shares of Novavax common stock, or 9.11% of the company, based on shares outstanding as of February 16, 2026.
Most shares are held through Shah Capital Opportunity Fund LP, which directly owns 14,000,000 shares, while Himanshu H. Shah personally owns 125,359 shares. The amendment discloses that all shares, other than Mr. Shah’s personal holdings, were acquired using investment capital through open-market purchases.
The filing also notes an April 8, 2026 open letter from Shah Capital to Novavax’s board stating its intention to vote against board nominees and executive compensation. The letter cites concerns such as value destruction, a pessimistic 2026 revenue forecast, low institutional credibility, cost discipline and profitability, and governance changes.
The Vanguard Group amended its Schedule 13G/A to report that it beneficially owns 0 shares of Novavax Inc. common stock, representing 0% of the class.
The amendment explains an internal realignment effective January 12, 2026 and states certain subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538. The form is signed by Ashley Grim on 03/27/2026.
Novavax Inc. director John W. Shiver exercised restricted stock units and received additional common shares as part of his equity compensation. On March 10, 2026, he converted 7,947 RSUs into 7,947 shares of Novavax common stock at a price of $0.00 per share.
Following the transactions, Shiver directly holds 7,947 shares of common stock and 15,893 restricted stock units. The RSUs from this grant are scheduled to vest in three equal installments on each of the first three anniversaries of March 10, 2025, assuming he continues to serve on Novavax’s board through each vesting date.
Novavax EVP, CFO and Treasurer James Patrick Kelly reported equity award activity involving restricted stock units (RSUs) and common stock. On March 7, 2026, 12,223 RSUs were exercised and converted into 12,223 shares of Novavax common stock at a stated price of $0.0000 per share.
On the same date, 5,904 shares of common stock were withheld by the company at $9.98 per share to satisfy tax withholding obligations related to the RSU vesting, as noted in the footnotes. After these transactions, Kelly directly held 130,599 shares of Novavax common stock. A related footnote states that one-third of the RSUs from this grant vest on each of the first three anniversaries of the March 7, 2023 grant date, subject to continued employment.
Novavax Executive Vice President, CFO and Treasurer James Patrick Kelly reported an amended insider filing reflecting a grant of 194,000 non‑statutory stock options awarded on March 2, 2026. One-quarter of the options vest on the first anniversary of that date, with the remaining three-quarters vesting in equal monthly installments over the following three years, all conditioned on continued employment. The amendment only updates the exercise price previously reported; all other details remain the same, and the options are held directly.